The global PEGylated proteins market is anticipated to grow at a considerable CAGR of 1.8% during the forecast period 2023-2030). The rising FDA approvals to increase therapeutic application of PEGylated proteins is a key factor driving the growth of the global PEGylated proteins market. For instance, in December 2022, Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.
Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked ?-galactosidase-A investigational product candidate. The FDA indicated in the BLA filing communication letter that the resubmitted BLA was considered a complete, class 2 response and set an action date of May 9, 2023, under the Prescription Drug User Fee Act (PDUFA).
To Request a Sample of our Report on PEGylated Proteins Market: https://www.omrglobal.com/request-sample/pegylated-proteins-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Products
- By Application
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Thermo Fisher Scientific, Inc., Abcam plc, Enzon Pharmaceuticals, Inc., Merck KGaA, and Celares GmbH among others
A full Report of PEGylated Proteins Market is Available @ https://www.omrglobal.com/industry-reports/pegylated-proteins-market
PEGylated Proteins Market Report Segment
By Products
- Consumables
- Services
By End-User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
By Application
- Cancer
- Autoimmune Diseases
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorders
- Other
PEGylated Proteins Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Abcam plc
- Aurigene Pharmaceutical Services Ltd.
- Celares GmbH
- Creative PEGworks
- Enzon Pharmaceuticals, Inc.
- Laysan Bio, Inc.
- Merck KGaA
- NOF America Corp.
- Profacgen
- Thermo Fisher Scientific, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pegylated-proteins-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
